Rechercher | Portail Régional BVS (2024)

The 2000HIV study: Design, multi-omics methods and participant characteristics.

Vos, Wilhelm A J W; Groenendijk, Albert L; Blaauw, Marc J T; van Eekeren, Louise E; Navas, Adriana; Cleophas, Maartje C P; Vadaq, Nadira; Matzaraki, Vasiliki; Dos Santos, Jéssica C; Meeder, Elise M G; Fröberg, Janeri; Weijers, Gert; Zhang, Yue; Fu, Jingyuan; Ter Horst, Rob; Bock, Christoph; Knoll, Rainer; Aschenbrenner, Anna C; Schultze, Joachim; Vanderkerckhove, Linos; Hwandih, Talent; Wonderlich, Elizabeth R; Vemula, Sai V; van der Kolk, Mike; de Vet, Sterre C P; Blok, Willem L; Brinkman, Kees; Rokx, Casper; Schellekens, Arnt F A; de Mast, Quirijn; Joosten, Leo A B; Berrevoets, Marvin A H; Stalenhoef, Janneke E; Verbon, Annelies; van Lunzen, Jan; Netea, Mihai G; van der Ven, Andre J A M.

Front Immunol ; 13: 982746, 2022.

Article de Anglais

| MEDLINE| ID: mdl-36605197

RÉSUMÉ

Background: Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets. Methods: The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort. Results: Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine. Conclusion: The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV.

Sujet(s)

COVID-19 , Infections à VIH , Minorités sexuelles , Mâle , Humains , Femelle , Infections à VIH/traitement médicamenteux , Infections à VIH/épidémiologie , hom*osexualité masculine , Études prospectives , Vaccins contre la COVID-19/usage thérapeutique , Épaisseur intima-média carotidienne , Études longitudinales ,

Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Martins, Laura J; Bonczkowski, Pawel; Spivak, Adam M; De Spiegelaere, Ward; Novis, Camille L; DePaula-Silva, Ana Beatriz; Malatinkova, Eva; Trypsteen, Wim; Bosque, Alberto; Vanderkerckhove, Linos; Planelles, Vicente.

AIDS Res Hum Retroviruses ; 32(2): 187-93, 2016 02.

Article de Anglais

| MEDLINE| ID: mdl-26171776

RÉSUMÉ

HIV-1 latently infected cells in vivo can be found in extremely low frequencies. Therefore, in vitro cell culture models have been used extensively for the study of HIV-1 latency. Often, these in vitro systems utilize defective viruses. Defective viruses allow for synchronized infections and circumvent the use of antiretrovirals. In addition, replication-defective viruses cause minimal cytopathicity because they fail to spread and usually do not encode env or accessory genes. On the other hand, replication-competent viruses encode all or most viral genes and better recapitulate the nuances of the viral replication cycle. The study of latency with replication-competent viruses requires the use of antiretroviral drugs in culture, and this mirrors the use of antiretroviral treatment (ART) in vivo. We describe a model that utilizes cultured central memory CD4(+) T cells and replication-competent HIV-1. This method generates latently infected cells that can be reactivated using latency reversing agents in the presence of antiretroviral drugs. We also describe a method for the removal of productively infected cells prior to viral reactivation, which takes advantage of the downregulation of CD4 by HIV-1, and the use of a GFP-encoding virus for increased throughput.

Sujet(s)

Lymphocytes T CD4+/virologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Agranulocytes/virologie , Modèles biologiques , Activation virale/physiologie , Latence virale/physiologie , Lymphocytes T CD4+/immunologie , Cellules cultivées , Régulation négative , Cytométrie en flux , Protéines à fluorescence verte/génétique , Infections à VIH/virologie , Humains , Réplication virale/physiologie